Centre Plans to Roll Out Biopharma SHAKTI Scheme by January 2027
The initiative aims to develop an end-to-end ecosystem for domestic production of biologics and biosimilars and position India as a global biopharmaceutical manufacturing hub.
The central government is set to implement Biopharma SHAKTI, a proposed INR 10,000 crore initiative aimed at strengthening India's domestic biopharmaceutical ecosystem, with the rollout targeted for January 2027.
Reportedly, the Department of Pharmaceuticals is in the process of finalising the policy framework, which is expected to be placed before the Union Cabinet for approval.
Speaking on the initiative, Satyaprakash T L, Joint Secretary, Department of Pharmaceuticals, said, “We are preparing to place the final policy before the Cabinet, and by January we will start its implementation.”
He added, “The scheme is designed to support CRDMOs to manufacture biopharmaceuticals, and strengthen the clinical research ecosystem to facilitate their development and testing.”
The initiative carries an outlay of INR 10,000 crore over five years, from FY2026-27 to FY2030-31.
Announced in the Union Budget 2026-27, Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) aims to develop an end-to-end ecosystem for domestic production of biologics and biosimilars and position India as a global biopharmaceutical manufacturing hub.
The scheme seeks to expand India's pharmaceutical manufacturing capabilities beyond conventional chemical-based drugs towards higher-value biopharmaceutical products, including biologics and biosimilars.
It will support contract research, development and manufacturing organisations (CRDMOs), while strengthening the infrastructure required for biopharmaceutical research, clinical development and testing.
The year-wise allocation of the INR 10,000 crore funding has not yet been specified
However, as per reports, the initial disbursement cycle will cover projects addressing non-communicable diseases, including diabetes, cancer, and autoimmune disorders.
The focus is intended to address the growing disease burden in India while supporting opportunities in the global biopharmaceutical market.
Stay tuned for more such updates on Digital Health News